文献速递传染病防控与疫情报告卫生政策与健康促进

更新:医务人员管理疑似电子烟或雾化产品使用相关肺损伤患者的临时指南——美国,2019年11月

Update: Interim Guidance for Health Care Providers for Managing Patients with Suspected E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, November 2019.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2019-11-22

美国CDC等机构正在调查全国性电子烟或雾化产品使用相关肺损伤(EVALI)爆发。EVALI仍为排除性诊断,无特异性检测或标志物,需临床判断。本报告总结在呼吸道感染(如流感)更流行时管理疑似或确诊EVALI患者的建议,包括询问电子烟使用史、脉搏血氧和胸部影像、考虑门诊管理、检测流感、慎用皮质类固醇、推荐戒烟 counseling 和年度流感疫苗接种。

要点

  • 询问有呼吸道、胃肠道或全身症状的患者是否使用电子烟或雾化产品。
  • 对疑似EVALI患者进行脉搏血氧测定,并根据临床指征获取胸部影像。
  • 临床稳定的EVALI患者符合特定标准时可考虑门诊管理;流感季节检测流感并遵循指南使用抗微生物药物。

核心结论

  • EVALI仍为排除性诊断,目前无特异性检测或标志物,评估应依据临床判断。
  • 在呼吸道感染更流行时,医务人员应按本报告建议管理疑似或确诊EVALI患者。

研究设计与样本

  • 本报告为CDC发布的临时指南更新,基于CDC、FDA、州和地方卫生部门及公共卫生和临床利益相关者的调查。

主要发现

  • EVALI患者症状可能与流感或其他呼吸道感染相似(如发热、咳嗽、头痛、肌痛或疲劳),初始评估时难以区分,且可能合并呼吸道感染。

关键数值与推荐

  • 询问有呼吸道、胃肠道或全身症状的患者关于电子烟或雾化产品使用。
  • 对疑似EVALI患者进行脉搏血氧测定,并根据临床指征获取胸部影像。
  • 对符合特定标准的临床稳定EVALI患者考虑门诊管理。
  • 检测流感,尤其在流感季节,并按照既定指南使用抗微生物药物包括抗病毒药物。
  • 门诊患者处方皮质类固醇需谨慎,因该治疗在门诊患者中研究不足,且可能加重呼吸道感染。

临床怎么用

  • 医务人员应询问有呼吸道、胃肠道或全身症状的患者是否使用电子烟或雾化产品。
  • 对疑似EVALI患者进行脉搏血氧测定,并根据临床指征获取胸部影像。
  • 临床稳定的EVALI患者符合特定标准时可考虑门诊管理。
  • 流感季节检测流感,并按照既定指南使用抗微生物药物包括抗病毒药物。
  • 门诊患者处方皮质类固醇需谨慎;推荐行为咨询帮助戒除电子烟;强调≥6个月人群每年接种流感疫苗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CDC, the Food and Drug Administration (FDA), state and local health departments, and public health and clinical stakeholders are investigating a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) (1). CDC has published recommendations for health care providers regarding EVALI (2-4). Recently, researchers from Utah and New York published proposed diagnosis and treatment algorithms for EVALI (5,6). EVALI remains a diagnosis of exclusion because, at present, no specific test or marker exists for its diagnosis, and evaluation should be guided by clinical judgment. Because patients with EVALI can experience symptoms similar to those associated with influenza or other respiratory infections (e.g., fever, cough, headache, myalgias, or fatigue), it might be difficult to differentiate EVALI from influenza or community-acquired pneumonia on initial assessment; EVALI might also co-occur with respiratory infections. This report summarizes recommendations for health care providers managing patients with suspected or known EVALI when respiratory infections such as influenza are more prevalent in the community than they have been in recent months (7). Recommendations include 1) asking patients with respiratory, gastrointestinal, or constitutional symptoms about the use of e-cigarette, or vaping, products; 2) evaluating those suspected to have EVALI with pulse oximetry and obtaining chest imaging, as clinically indicated; 3) considering outpatient management for clinically stable EVALI patients who meet certain criteria; 4) testing patients for influenza, particularly during influenza season, and administering antimicrobials, including antivirals, in accordance with established guidelines; 5) using caution when considering prescribing corticosteroids for outpatients, because this treatment modality has not been well studied among outpatients, and corticosteroids could worsen respiratory infections; 6) recommending evidence-based treatment strategies, including behavioral counseling, to help patients discontinue using e-cigarette, or vaping, products; and 7) emphasizing the importance of annual influenza vaccination for all persons aged ≥6 months, including patients who use e-cigarette, or vaping products.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Jatlaoui TC, Wiltz JL, Kabbani S, et al. Update: Interim Guidance for Health Care Providers for Managing Patients with Suspected E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, November 2019. MMWR Morb Mortal Wkly Rep. 2019. PMID: 31751322. doi:10.15585/mmwr.mm6846e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。